Similar articles

• Adverse events related to muraglitazar use in diabetes.

  Najman DM. Najman DM. JAMA. 2006 May 3;295(17):1997; author reply 1998. doi: 10.1001/jama.295.17.1997-a. JAMA. 2006. PMID: 16670404 No abstract available.
• Selling safety--lessons from muraglitazar.

  Brophy JM. Brophy JM. JAMA. 2005 Nov 23;294(20):2633-5. doi: 10.1001/jama.294.20.jed50074. Epub 2005 Oct 20. JAMA. 2005. PMID: 16239638 No abstract available.
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  Nissen SE, Wolski K, Topol EJ. Nissen SE, et al. JAMA. 2005 Nov 23;294(20):2581-6. doi: 10.1001/jama.294.20.joc50147. Epub 2005 Oct 20. JAMA. 2005. PMID: 16239637
• The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.

  Kalliora C, Drosatos K. Kalliora C, et al. J Cardiovasc Pharmacol. 2020 Nov;76(5):514-526. doi: 10.1097/FJC.0000000000000891. J Cardiovasc Pharmacol. 2020. PMID: 33165133 Free PMC article. Review.
• Muraglitazar (Bristol-Myers Squibb/Merck).

  Barlocco D. Barlocco D. Curr Opin Investig Drugs. 2005 Apr;6(4):427-34. Curr Opin Investig Drugs. 2005. PMID: 15898350 Review.